tirzepatide availability us FDA Clarifies Compounding Rules as Supply Stabilizes Tirzepatide Market Size to Touch

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management

Peak Wellness charges $349 a month month-to-month with no commitment, flat across every dose tier

The manufacturer, Eli Lilly, has a patent on the drug until January 5, 2036, at which point you may be able to find generic versions

Stopping treatment is unnecessary and interrupts weight loss progress

How Tirzepatide Is Different Tirzepatide is often described as a dual agonist because it targets two hormone systems: GLP1 and GIP (glucosedependent insulinotropic polypeptide)

New England Journal of Medicine (2022) This landmark phase 3 trial evaluated tirzepatide in 2,539 adults with obesity or overweight without diabetes over 72 weeks